Actively Recruiting
Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease
Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2025-01-23
360
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
Sponsors
I
Institut National de la Santé Et de la Recherche Médicale, France
Lead Sponsor
I
IHU-A-ICM, Paris, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Observational, prospective, monocentric study to assess clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients and rate of progression compared to healthy controls (HC) and subjects at risk to develop PD. The primary objective of this study is to identify clinical, imaging and biologic markers of PD onset and progression for use in clinical trials of disease-modifying therapies.
CONDITIONS
Official Title
Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years and older
- Mini-Mental State Examination (MMSE) score greater than 26
- Negative pregnancy test for women who could become pregnant
- Idiopathic Parkinson disease diagnosed according to UK Parkinson's Disease Society Brain Bank criteria with disease duration less than 3 years
- Genetic Parkinson disease diagnosis with confirmed mutation in parkin, LRRK2, SNCA, or GBA genes
- Prodromal subjects with a relative with genetically confirmed Parkinson disease or diagnosis of idiopathic REM sleep Behavior Disorder with normal neurological exam
- Healthy subjects with normal neurological examination
You will not qualify if you...
- Psychiatric disorder or any progressive life-threatening disease
- Conditions preventing understanding or following study instructions
- Contraindications to MRI or SPECT scans
- Parkinson disease subjects without dopamine transporter deficit on SPECT scan
- Parkinsonism caused by neuroleptics or recent neuroleptic use within 6 months
- Atypical parkinson syndromes such as MSA, PSP, or CBD
- Parkinson disease subjects with genetic mutations having other atypical parkinson disease syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases
- Current or recent use of neuroleptics within 6 months
- Any biological abnormalities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Pitié-Salpêtrière
Paris, France, 75013
Actively Recruiting
Research Team
M
Marie VIDAILHET, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here